Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T19:58:34.183Z.
Calculation as of: 2026-10-06T19:58:34.183Z.
Quote observation: 2026-10-06T19:55:24.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 954f90b5803147d7e77bb33cb230df589f2ac0b2215919e8afc4fbf9605c1a4a
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Market Cap
$217.50M
EBITDA Yield
N/A
TTM Avg
143.11%
3Y Avg
143.11%
5Y Avg
143.11%
Market Cap
$215.58M
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$212.65M
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$212.25M
EBITDA Yield
7.06%
TTM Avg
4.54%
3Y Avg
3.13%
5Y Avg
3.13%
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Profound Medical Corp. (PROF) | $220.93M | N/A | N/A | N/A | N/A |
| Keros Therapeutics, Inc. (KROS)vs › | $217.50M | N/A | 143.11% | 143.11% | 143.11% |
| Nautilus Biotechnolgy, Inc. (NAUT)vs › | $225.88M | N/A | N/A | N/A | N/A |
| Prelude Therapeutics Incorporated (PRLD)vs › | $215.58M | N/A | N/A | N/A | N/A |
| Biodesix, Inc. (BDSX)vs › | $227.60M | N/A | N/A | N/A | N/A |
| Lyell Immunopharma, Inc. (LYEL)vs › | $212.94M | N/A | N/A | N/A | N/A |
| Anbio Biotechnology Class A Ordinary Shares (NNNN)vs › | $212.65M | N/A | N/A | N/A | N/A |
| Niagen Bioscience Inc (NAGE)vs › | $212.25M | 7.06% | 4.54% | 3.13% | 3.13% |
| Sionna Therapeutics, Inc. (SION)vs › | $211.53M | N/A | N/A | N/A | N/A |
| Vogenx Inc. (VOGX)vs › | $225.94M | N/A | N/A | N/A | N/A |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
